Gunnett C A, Lund D D, Howard M A, Chu Y, Faraci F M, Heistad D D
Department of Medicine, University of Iowa College of Medicine and Veterans Affairs Medical Center, Iowa City, Iowa 52242-1081, USA.
Stroke. 2002 Sep;33(9):2292-6. doi: 10.1161/01.str.0000027427.86177.d4.
These studies evaluated whether gene transfer of inducible nitric oxide synthase (iNOS) is a sufficient stimulus to produce vascular dysfunction in cerebral arteries.
Intracranial (pial) arteries were dissected from human brain tissue obtained during elective surgery. Isolated human arteries were incubated in vitro with adenovirus containing iNOS (AdiNOS) or a nonexpressive transgene (control, AdBglII) (500 micro L, 3x10(9) plaque-forming units per milliliter), and vascular function was examined 24 hours later. In anesthetized rabbits, AdiNOS or AdBglII (300 microL 1x10(10)) was injected into the cisterna magna. Three days later, the basilar artery was removed, and reactivity was examined ex vivo.
In submaximally precontracted vessels, we observed impairment of NO-dependent relaxation in human cerebral arteries after gene transfer of iNOS. Maximum relaxation to bradykinin (1 micromol/L, an endothelium-dependent agonist) was 77+/-11% (mean+/-SE) after AdBglII and 31+/-22% (P<0.05) after AdiNOS. After AdiNOS, responses to nitroprusside (an endothelium-independent NO donor) also were impaired. Responses to both nitroprusside and bradykinin were improved by aminoguanidine (300 micromol/L), an inhibitor of iNOS. AdiNOS produced no change in vasoconstrictor responses to U46619. In basilar arteries from rabbits examined in vitro after gene transfer in vivo, responses to histamine, serotonin, and nitroprusside all were similar after AdiNOS or AdBglII. In contrast, relaxation to acetylcholine was significantly depressed after AdiNOS. Maximum relaxation to acetylcholine (10 micromol/L) was 90+/-3% after AdBglII and 68+/-5% (P<0.05) after AdiNOS. Relaxation of arteries after AdiNOS was improved by aminoguanidine.
These studies suggest that expression of iNOS may impair NO-dependent relaxation in both human and rabbit cerebral arteries.
这些研究评估了诱导型一氧化氮合酶(iNOS)基因转移是否足以刺激脑动脉产生血管功能障碍。
从择期手术获取的人脑组织中分离出颅内(软脑膜)动脉。将分离出的人动脉在体外与含iNOS的腺病毒(AdiNOS)或无表达的转基因(对照,AdBglII)(500微升,每毫升3×10⁹ 噬斑形成单位)一起孵育,24小时后检测血管功能。在麻醉的兔中,将AdiNOS或AdBglII(300微升,1×10¹⁰)注入小脑延髓池。三天后,取出基底动脉,离体检测其反应性。
在次最大预收缩血管中,我们观察到iNOS基因转移后人脑动脉中一氧化氮依赖性舒张功能受损。AdBglII处理后对缓激肽(1微摩尔/升,一种内皮依赖性激动剂)的最大舒张率为77±11%(平均值±标准误),AdiNOS处理后为31±22%(P<0.05)。AdiNOS处理后,对硝普钠(一种内皮非依赖性一氧化氮供体)的反应也受损。iNOS抑制剂氨基胍(300微摩尔/升)可改善对硝普钠和缓激肽的反应。AdiNOS对U46619的血管收缩反应无变化。在体内基因转移后体外检测的兔基底动脉中,AdiNOS或AdBglII处理后对组胺、5-羟色胺和硝普钠的反应均相似。相比之下,AdiNOS处理后对乙酰胆碱的舒张反应明显降低。AdBglII处理后对乙酰胆碱(10微摩尔/升)的最大舒张率为90±3%,AdiNOS处理后为68±5%(P<0.05)。氨基胍可改善AdiNOS处理后动脉的舒张。
这些研究表明,iNOS的表达可能损害人和兔脑动脉中的一氧化氮依赖性舒张。